The attractiveness of the inhibition of VEGFR signaling for GIST therapy is evidenced by the multiple completed and ongoing clinical trials (reviewed in detail by Catalano F. with co-authors) [63]. Here, KDR is linked to gastrointestinal stromal tumor.